RT Journal Article
SR Electronic
T1 Recombinant alpha interferon for chronic hepatitis B in anti-HIV positive patients receiving zidovudine.
JF Gut
JO Gut
FD BMJ Publishing Group Ltd and British Society of Gastroenterology
SP S106
OP S106
DO 10.1136/gut.34.2_Suppl.S106
VO 34
IS 2 Suppl
A1 P Marcellin
A1 N Boyer
A1 J F Colin
A1 M Martinot-Peignoux
A1 V Lefort
A1 S Matheron
A1 S Erlinger
A1 J P Benhamou
YR 1993
UL http://gut.bmj.com/content/34/2_Suppl/S106.abstract
AB In this pilot study of the effects of interferon alfa in 10 anti-HIV positive, chronic hepatitis B patients treated with zidovudine (AZT), tolerance to interferon was good and similar to that in anti-HIV negative patients. After treatment, the HIV stage and CD4 lymphocyte count were unchanged. In two patients hepatitis B virus (HBV)-DNA and hepatitis B e antigen (HBeAg) disappeared and the serum alanine aminotransferase (ALT) returned to normal; loss of hepatitis B surface antigen (HBsAg) with absence of histopathological activity was observed after treatment in one of these patients. These preliminary results need to be confirmed by a larger study.